ERBB2 and neoplasm: The preclinical studies showed that R-LM113 played a role in cancer treatment and prolonged survival in immunodeficient and immunocompetent mice, whereas R-LM249 can infect and kill solely HER-2-overexpressed cancer cells and can reduce the tumor growth and inhibit carcinomatosis efficiently (Nanni et al., 2013).